Skye Bioscience, Inc.SKYENASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+46.8%
5Y CAGR+55.9%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+46.8%/yr
vs +40.5%/yr prior
5Y CAGR
+55.9%/yr
Recent deceleration
Acceleration
+6.3pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
9.2x
Strong expansion
Streak
1 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $57.98M | +92.0% |
| 2024 | $30.19M | -13.1% |
| 2023 | $34.74M | +89.7% |
| 2022 | $18.31M | +133.3% |
| 2021 | $7.85M | +24.8% |
| 2020 | $6.29M | -5.2% |
| 2019 | $6.63M | +41.3% |
| 2018 | $4.69M | +21.6% |
| 2017 | $3.86M | -13.7% |
| 2016 | $4.47M | - |